Cardiovascular Disease

>

Latest News

Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups
Semaglutide Supports Long-Term Weight Loss, Reduces CV Risk Across BMI Subgroups

May 15th 2024

Analyses of the SELECT trial found mean weight loss of 10.2% sustained for 4 years and comparable CV benefit with weight loss greater or less than 5%, or even weight gain.

May Issue of Patient Care Online Digital Edition is Now Live
May Issue of Patient Care Online Digital Edition is Now Live

May 14th 2024

Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study
Poor Cardiovascular-Kidney-Metabolic Health “Widespread” among US Adults, According to New Study

May 8th 2024

Children with HTN Have 2-times Higher Risk of Major Adverse Cardiac Events, According to New Research / Image credit: ©New Africa/AdobeStock
Children with HTN Have 2-times Higher Risk of Major Adverse Cardiac Events, According to New Research

May 7th 2024

©psdesign1/stock.adobe.com
CV Risk Prevention Profiles Significantly Worse Following Stroke vs MI in 2 Large National Cohorts

May 6th 2024

More News

© 2024 MJH Life Sciences

All rights reserved.